Chelates Drug Delivery Materials: Advanced Coordination Chemistry And Targeted Therapeutic Systems

Fundamental Principles Of Chelate-Based Drug Delivery Systems

Chelate-based drug delivery materials operate through the formation of coordinate bonds between metal ions and electron-donating ligands, creating stable yet reversible complexes that can encapsulate and transport therapeutic agents 913. The coordinate bond, also termed a dipolar bond, represents a specialized covalent interaction wherein both electrons originate from the same atom—typically a Lewis base donating a lone pair to a Lewis acid metal center 9. This coordination chemistry enables precise control over drug loading, release kinetics, and targeting specificity.

The formation of chelate complexes requires two essential conditions: first, the metal ion must possess an incomplete electron octet (common in transition metals such as Fe³⁺, Cu²⁺, Zn²⁺, and lanthanides like Gd³⁺); second, the ligand must provide accessible lone pair electrons through functional groups including carboxylic acids, amines, thiols, phosphonic acids, or heterocyclic nitrogen donors 913. The resulting metal-ligand architecture can accommodate drug molecules bearing electron-donating functionalities—such as alcohols, ketones, furans, pyrroles, pyridines, imidazoles, and sulfonamides—thereby forming ternary chelating complex micelles (CCM) 913.

Key advantages of chelate-based delivery include: (1) exceptionally high drug loading capacity within the chelate core, reducing the total lipid or polymer dose required 12; (2) protection of encapsulated therapeutics from enzymatic degradation and harsh physiological environments, including gastric acid 346; (3) prolonged circulation half-life through evasion of renal clearance, enhancing accumulation in target tissues such as liver and spleen 12; (4) reduced dosing frequency and improved patient compliance due to sustained release profiles 12; and (5) the ability to co-deliver counter ions (e.g., Zn²⁺, Mg²⁺, Ca²⁺) to mitigate depletion of endogenous metals, a common side effect of chelation therapy 12.

Molecular Architecture And Structural Variants Of Chelates Drug Delivery Materials

Chelating Complex Micelles (CCM) With Metal Ion Cores

Chelating complex micelles represent a prominent structural class wherein block copolymers containing chelating segments self-assemble around metal ion cores 913. A typical CCM comprises: (i) a hydrophobic chelating block (e.g., polyglutamic acid, PGA) that coordinates metal ions and drug molecules through multiple binding sites; (ii) a hydrophilic neutral block (e.g., polyethylene glycol, PEG) that enhances aqueous dispersibility and provides stealth properties to evade immune recognition 13. The metal center—often a transition metal or lanthanide—serves as a coordination hub, simultaneously binding to polymer ligands and drug molecules possessing electron-donating groups 913.

The chelating ligands can be classified by denticity: unidentate ligands (single binding site), bidentate ligands (two binding sites, e.g., ethylenediamine), tridentate ligands (three sites), hexadentate ligands (six sites, e.g., EDTA), and polydentate ligands (multiple sites) 13. Higher denticity generally confers greater thermodynamic stability to the metal-drug complex, reducing premature drug release during circulation 12. For instance, EDTA (ethylenediamine tetraacetic acid) and DTPA (diethylenetriaminepentaacetic acid) are hexadentate chelators widely employed in metal removal therapies and as components of drug delivery formulations 12.

Experimental studies demonstrate that CCM formulations can achieve drug loading efficiencies exceeding 80% while maintaining colloidal stability in physiological buffers for over 48 hours at 37°C 9. The coordinate bond strength can be tuned by selecting appropriate metal-ligand pairs: softer Lewis acids (e.g., Cu⁺, Ag⁺) preferentially bind soft bases (e.g., thiols), whereas hard Lewis acids (e.g., Fe³⁺, Al³⁺) favor hard bases (e.g., carboxylates, phosphates) 913.

Cochleate Delivery Vehicles: Lipid-Cation Precipitates

Cochleate delivery vehicles constitute another major category of chelate-based carriers, formed by the interaction of anionic phospholipids (primarily phosphatidylserine, PS) with divalent cations such as Ca²⁺ 346. These structures adopt a unique rolled-sheet morphology comprising multiple solid bilayer sheets, creating a series of concentric lipid layers that encapsulate hydrophobic and amphiphilic drugs within the interlamellar spaces 346.

The bilayer architecture of cochleates provides exceptional protection against enzymatic degradation: even when outer layers are exposed to harsh conditions (e.g., gastric pH 1.5–2.0, pancreatic lipases), the interior layers remain intact, preserving encapsulated therapeutics 346. This property enables oral bioavailability of otherwise labile compounds, including amphotericin B (an antifungal polyene), large DNA constructs for gene therapy, peptide drugs, and antibiotics such as clofazimine 346.

Cochleates can be manufactured via two primary routes: (i) the trapping method, wherein liposomes containing the drug are treated with Ca²⁺ to induce bilayer fusion and cochleate formation; (ii) the hydrogel method, involving direct mixing of PS, drug, and Ca²⁺ in aqueous media 346. Lyophilization of cochleates to a dry powder has no adverse effects on morphology or function, and reconstituted formulations retain activity after storage for >2 years at 4°C or >1 year at room temperature as lyophilized powder 346.

Soy-derived phosphatidylserine (soy PS) is particularly advantageous for cochleate production due to its commercial availability, low cost, and established safety profile as a nutritional supplement 346. Non-purified soy PS (40% purity) has been used in clinical studies for cognitive enhancement in elderly populations, demonstrating favorable tolerability 346.

Polycation-Chelator Conjugates For Nucleic Acid Delivery

Polycation-based chelate systems exploit the electrostatic interaction between cationic polymers (e.g., polylysine, polyarginine, polyethylenimine, DEAE-dextran) and anionic nucleic acids (DNA, RNA), with chelators such as crown ethers or DOTA derivatives incorporated to modulate cellular uptake and endosomal escape 1. The chelator component serves multiple functions: (i) facilitating attachment of the polycation-DNA complex to polyanionic cell surfaces via cross-bridging; (ii) protecting DNA from nuclease degradation during extracellular transit; (iii) disrupting endosomal membranes to enable cytoplasmic release of the genetic cargo 1.

Polyethylenimine (PEI) is particularly effective due to its intrinsic "proton sponge" effect: the high density of amine groups buffers endosomal acidification, causing osmotic swelling and membrane rupture 1. Incorporation of chelators such as crown ethers into PEI conjugates further enhances transfection efficiency by promoting ion flux across endosomal membranes 1. Experimental data indicate that PEI-crown ether conjugates achieve 3–5-fold higher gene expression compared to unmodified PEI in HeLa and HEK293 cell lines 1.

Smart Theranostic Systems: Dual Nuclear-Medical And Cytotoxic Chelates

Advanced chelate-based delivery systems integrate diagnostic imaging capabilities with therapeutic action, enabling real-time monitoring of drug biodistribution and treatment response 1019. A representative theranostic design comprises: (i) a chelating agent (Chel) capable of complexing radioisotopes (e.g., ⁶⁴Cu, ⁶⁸Ga, ⁹⁰Y, ¹⁷⁷Lu) for positron emission tomography (PET) or single-photon emission computed tomography (SPECT) imaging; (ii) a cytotoxic compound (CT) such as a chemotherapeutic drug or radionuclide emitter; (iii) a biological targeting vector (TV) such as an antibody, peptide, or small-molecule ligand that recognizes tumor-associated antigens; and (iv) linkers (L) and spacers (S) that control the spatial arrangement and release kinetics of the components 10.

For example, a compound with the structure CT-L1-Chel-S1-TV can deliver both a cytotoxic payload and a diagnostic radioisotope to tumor cells expressing the target antigen, enabling simultaneous therapy and imaging (theranostics) 10. The chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) is widely employed due to its high affinity for trivalent lanthanides and radiometals, forming kinetically inert complexes that resist transchelation in vivo 1819. DOTA-Gd³⁺ complexes serve as FDA-approved MRI contrast agents, while DOTA-⁹⁰Y and DOTA-¹⁷⁷Lu conjugates are used in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors 1819.

Gadolinium-based chelates exhibit paramagnetic properties and slow electronic relaxation times (T₁ ~ 3–5 ms at 1.5 T), enhancing MRI signal intensity in tissues where they accumulate 19. High-generation PAMAM dendrimers conjugated with multiple DOTA-Gd³⁺ units (G5–G10) demonstrate improved rotational correlation times (τR ~ 10–50 ns), yielding superior contrast resolution compared to monomeric agents 19.

Synthesis Routes And Formulation Strategies For Chelates Drug Delivery Materials

Preparation Of Chelating Complex Micelles

The synthesis of CCM involves a two-step coordination process 913:

1. Metal-Polymer Complexation: A block copolymer containing chelating ligands (e.g., PEG-b-PGA) is dissolved in aqueous buffer (pH 6.5–7.4, 10 mM phosphate) at a concentration of 5–20 mg/mL. A metal salt solution (e.g., FeCl₃, ZnSO₄, CuCl₂) is added dropwise under stirring (500 rpm, 25°C) to achieve a metal:ligand molar ratio of 1:2 to 1:5, allowing coordination bonds to form over 30–60 minutes 913.

2. Drug Loading via Coordinate Bonding: The drug molecule, bearing electron-donating functional groups, is dissolved in a compatible solvent (e.g., DMSO, ethanol) and added to the metal-polymer solution at a drug:metal molar ratio of 1:1 to 2:1. The mixture is stirred for an additional 2–4 hours at 25–37°C to allow ternary complex formation 913. Unencapsulated drug and free metal ions are removed by dialysis (MWCO 3.5–10 kDa) against deionized water or saline for 24–48 hours, with buffer changes every 6 hours 913.

Critical parameters influencing CCM properties include: (i) metal ion selection—transition metals (Fe³⁺, Cu²⁺, Zn²⁺) provide moderate binding strength suitable for controlled release, whereas lanthanides (Gd³⁺, Eu³⁺) offer higher stability for imaging applications 91319; (ii) polymer molecular weight—higher MW (>10 kDa) enhances circulation time but may reduce cellular uptake 13; (iii) pH—acidic conditions (pH <5) can protonate carboxylate ligands, weakening metal coordination and triggering drug release in endosomal compartments 913.

Cochleate Formulation Via Trapping And Hydrogel Methods

Trapping Method: Liposomes are first prepared by thin-film hydration or extrusion, incorporating the drug into the lipid bilayer or aqueous core 346. Phosphatidylserine (soy PS, 10–50 mg/mL) is mixed with neutral lipids (e.g., DOPC, cholesterol) at molar ratios of 7:3 to 9:1 PS:neutral lipid. The lipid mixture is hydrated in buffer (10 mM HEPES, pH 7.4) containing the drug (1–10 mg/mL) and extruded through polycarbonate membranes (100–200 nm pore size) to generate unilamellar vesicles 346. Calcium chloride solution (50–200 mM) is then added dropwise to the liposome suspension under gentle stirring (200 rpm, 25°C), inducing bilayer fusion and cochleate formation over 15–30 minutes 346. The resulting cochleates are collected by centrifugation (10,000 × g, 10 min) and resuspended in Ca²⁺-containing buffer (5–10 mM CaCl₂) for storage 346.

Hydrogel Method: Soy PS (20–100 mg/mL) is dissolved in chloroform:methanol (2:1 v/v), and the organic solvent is evaporated under nitrogen to form a lipid film 346. The film is hydrated with an aqueous solution containing the drug (1–10 mg/mL) and CaCl₂ (50–100 mM) at 50–60°C for 30–60 minutes with intermittent vortexing 346. The mixture spontaneously forms cochleates, which are then lyophilized to a powder for long-term storage 346.

Lyophilized cochleates retain structural integrity and drug content for >1 year at room temperature, and reconstitution in aqueous media (saline, PBS) restores the original morphology within 5–10 minutes 346. Stability studies using transmission electron microscopy (TEM) and dynamic light scattering (DLS) confirm that cochleate diameter (0.5–2.0 μm) and polydispersity index (PDI <0.3) remain unchanged after lyophilization-reconstitution cycles 346.

Liposomal Encapsulation Of Metal Chelating Agents

Liposomal formulations of chelating agents (e.g., EDTA, DTPA, deferoxamine) are prepared by remote loading techniques to achieve high encapsulation efficiency (>90%) 12. A pH gradient method is commonly employed: liposomes composed of DSPC:cholesterol (55:45 molar ratio) are prepared by extrusion (100 nm pore size) in citrate buffer (pH 4.0, 300 mM) 12. The external buffer is exchanged to neutral pH (7.4) by dialysis or gel filtration, creating a transmembrane pH gradient (ΔpH ~ 3 units) 12. The chelating agent (e.g., EDTA disodium salt, 50–200 mM) is added to the liposome suspension and incubated at 60°C for 30–60 minutes, during which the uncharged or weakly charged chelator diffuses across the lipid bilayer and becomes protonated and trapped in the acidic intraliposomal space 12.

This approach yields